Can CD40, CTLA4, and SH2B3 variants increase autoimmune thyroid risk?

Genetic predisposition plays a critical role in disrupting immune tolerance, particularly in middle-aged individuals who face a higher baseline risk for thyroid autoimmunity. Key genetic variants in CD40, CTLA4, and SH2B3 collectively impair immune-regulatory checkpoints, shifting systemic regulation toward self-reactivity and thyroid tissue targeting.

Mechanistic pathways

• CD40 rs1883832 (C allele): Located in the Kozak consensus sequence, this variant increases CD40 translation efficiency and protein expression by 13% to 35%, intensifying B-cell activation and antigen-presenting cell costimulation.
• CTLA4 rs231775 (+49A/G, G allele): This variant weakens the inhibitory capacity of the CTLA-4 receptor on T-cell activation, leading to compromised immunological down-regulation and unchecked T-cell proliferation.
• SH2B3 rs3184504: This missense variant disrupts negative feedback within hematopoietic cytokine pathways, altering JAK-STAT signaling dynamics and facilitating prolonged inflammatory activity.

Clinical evidence and thyroid pathology

• Graves' disease and Hashimoto's thyroiditis: The failure of these molecular checkpoints directly increases susceptibility to autoimmune thyroid diseases (AITD). CD40 risk variants predominantly drive Graves' disease by promoting TSH-receptor autoantibody production.
• Thyroid antibody production: The CTLA4 rs231775 variant functions as a broad risk locus for both Graves' and Hashimoto's, correlating with elevated thyroid peroxidase (TPO) and thyroglobulin (TG) antibodies. Meanwhile, the SH2B3 rs3184504 variant is linked to autoimmune hypothyroidism and elevated TPO antibody titers.

Bottom line

• Genetic variants in CD40, CTLA4, and SH2B3 impair essential immune-regulatory checkpoints, directly increasing susceptibility to thyroid autoimmunity and driving the production of clinically significant thyroid autoantibodies.